$RNAZ

Transcode Therapeutics, Inc. (RNAZ) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Director On September 1

Several biotech stocks are trading higher in premarket, including Autonomix Medical (AMIX) up 29% at $6.92, Picard Medical (PMI) up 12% at $5.85, and others. The gains indicate early momentum and potential volatility for the trading day, according to the market activity.

Tenon Medical (TNON) shares rose 80% after-hours with no specific news, reporting Q2 revenue of $1.3M (up 127% YoY) and a net loss of $4.1M. BioVie (BIVI) gained 55% after positive Phase 2 trial results for its Parkinson's drug. Edesa Biotech (EDSA) advanced 7% after announcing Phase 2 trial preparations for vitiligo treatment. TransCode (RNAZ) and HCW Biologics (HCWB) also saw after-hours gains on trial updates.

RedChip Companies says it will air interviews on Bloomberg TV and CNBC featuring Virax Biolabs Group Ltd. (Nasdaq:VRAX) and Transcode Therapeutics Inc. (Nasdaq:RNAZ). Virax CEO James Foster discusses post-fiscal 2026 balance sheet and Nasdaq bid compliance, plus ImmuneSelect supply talks. Transcode CEO Philippe Calais covers TTX-MC138 Phase 2a progress in ctDNA+ colorectal cancer.

Transcode Therapeutics, Inc. (RNAZ) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001829635 0001829635 2026-07-20 2026-07-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Biotech stocks rose on company-specific catalysts. Virax Biolabs (VRAX) jumped over 100% after signing an exclusive multi-country supply agreement with Fosun Diagnostics for ImmuneSelect. Forte Biosciences (FBRX) gained about 78% on positive Phase 1b vitiligo data for FB102. First Tracks (TRAX) rose ~56% without news. TransCode (RNAZ) and Connect Biopharma (CNTB) also climbed; Sanuwave (SNWV) fell guidance and expects Q2 revenue of $8.5m to $9.5m.

Biotech stocks rose on varied catalysts. Parabilis (PBLS) debuted on Nasdaq, up 58% to $31.60 after pricing a $20.00 IPO of 33.5M shares for ~$670M gross proceeds. Clover Health (CLOV) gained 14% to $4.89 after a court ruling upgraded its 2026 PPO Star Rating to 4.5 from 3.5. Myomo (MYO) rose 17% to $1.54; Shoulder Innovations (SI) up 17% to $17.89; GMRS up 13% to $13.18.

TransCode Therapeutics (NASDAQ: RNAZ) has filed a shelf registration (Form S-3) to allow selling stockholders to resell up to 15.96 million shares of common stock. The company will not receive any proceeds from these sales. The filing details the outstanding shares, conversion mechanics for preferred stock, and outlines various clinical and pipeline developments for its therapeutic candidates, including TTX-MC138 and Seviprotimut-L.

TransCode Therapeutics, Inc. (RNAZ) has delayed the filing of its 2025 Form 10-K, citing complex accounting requirements following several significant transactions on October 8, 2025. These include the acquisition of ABCJ, LLC, a $25 million private placement of Series B preferred stock, and the issuance of contingent value rights (CVRs). The company requires additional time to finalize valuations and accounting for various items like IPR&D, goodwill, and deferred taxes.

TransCode Therapeutics, Inc. has appointed Jack E. Stover to its Board of Directors, where he will also join the Audit and Nominating Committees. Mr. Stover brings over three decades of executive leadership experience in life sciences, including drug development, diagnostics, and capital formation. The company anticipates his expertise will be invaluable as they advance their RNA and immuno-oncology pipelines.